Prof Rohini Sharma

Professor Rohini Sharma is a Reader in Clinical Pharmacology and Medical Oncology, Imperial College London. She is Medical Oncology lead for Liver Cancer and Neuroendocrine Cancers. She treats all gastrointestinal malignancies.
Bio
Rohini Sharma is a Reader in Clinical Pharmacology and Medical Oncology. She is Oncology Lead for Liver Cancer and Neuroendocrine Cancers at the Hammersmith Hospital, Imperial College Healthcare NHS Trust. Prof Sharma is the lead of the liver cancer research group at Imperial College.
Professor Sharma is a lead practitioner in the delivery of Selective Internal Radiotherapy Treatment (SIRT) for the management of liver cancer and peptide receptor radiotherapy treatment (PRRT) for the management of Neuroendocrine tumours.
Rohini Sharma completed her medical training at the University of Adelaide, Australia and undertook her specialist oncology training at the Royal Prince Alfred Hospital, Sydney and her clinical pharmacology training at Westmead Hospital, Sydney. Rohini was awarded an NHMRC Fellowship to complete her PhD at the Westmead Millennium Institute, University of Sydney, Australia. She was awarded the prestigious Higher Education Funding Council for England Clinical Senior Lecturer position in May 2010.
Her current research interests include early phase clinical trials, drug development and PET imaging. Her group is also involved in the discovery and validation of novel targeted therapies for the management of HCC and NET. She is author of over 80 publications in these areas.
More information
116 Harley Street
London W1G 7JL
- Senior Lecturer Medical Oncology & Clinical Pharmacology
Imperial College, London - Honorary Consultant, Medical Oncology
Imperial College Healthcare Trust
- Senior Lecturer Medical Oncology & Clinical Pharmacology
Imperial College, London
- Upper GI cancer
- Neuroendocrine tumours
- Clinical pharmacology
- Year qualified 1999
- University of Adelaide 1999
- University of Sydney 2010
Dr Sharma specialises in the delivery of directed radiation treatment namely selective internal radiation therapy (SIRT) to the liver and Lutathera.